Last reviewed 2026-04-20 · How we verify

IMids

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Anaemia
• Arthralgia
• Fatigue
• Weight increased
• Pyrexia
• Dyspnoea
• Constipation
• Headache
• Hypertension
• Cough
• Pruritus
• Abdominal pain

Key clinical trials

• A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma (PHASE2)
• Study of T Cells Targeting CD19/BCMA (CART-19/BCMA) for High Risk Multiple Myeloma Followed With Auto-HSCT (PHASE1, PHASE2)
• Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies (PHASE1)
• Vaginal Self-sampling for Detecting High-risk Human Papillomavirus Cervical Infection in Patients With Immune-mediated Inflammatory Diseases (NA)
• Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases
• Evaluation of the Use of Apixaban in Prevnetion of Thromboembolic Disease in Patients With Myeloma Trated With iMiDs (PHASE3)
• Real-world Effectiveness of Ustekinumab in Participants Suffering From Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) With Extra-intestinal Manifestations or Immune-mediated Inflammatory Diseases
• First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• IMids CI brief — competitive landscape report
• IMids updates RSS · CI watch RSS
• Onward Therapeutics portfolio CI